After Vaccine Freeze, European Countries Seek a Quick Thaw

First, France abruptly halted AstraZeneca vaccinations. Now, the French prime minister wants to get one as soon as he can.

With the virus rebounding from Paris to Budapest and beyond, European governments that rushed to suspend use of AstraZeneca vaccines after reports of blood clots are realizing the far-reaching impact of the move. And they suddenly seem eager for any signal — or fig leaf — that allows them to resume the shots.

That could come as soon as Thursday, when the European Medicines Agency releases initial results of its investigations into whether there is a connection between the vaccine and the blood clots. So far, the EMA and World Health Organization have said there’s no evidence the vaccine is to blame.

But experts worry that the damage already has been done. The suspensions by Germany, France, Italy, Spain and others have fueled doubts about the oft-maligned AstraZeneca vaccine, and vaccination efforts in general, as the world struggles to vanquish the pandemic.

“There are thousands of new cases in Germany, France, Italy, etc. every day. If you are halting vaccination during this ongoing pandemic, you know that people will die,” Michael Head, senior research fellow in global health at the University of Southampton, told The Associated Press.

While stressing the importance of investigating potentially dangerous side effects of a vaccine, he said, “It’s totally possible to investigate the signals without stopping the vaccine rollout.”

Some countries are sticking to the AstraZeneca vaccines. India has vowed to continue vaccinations, and Brazil’s health minister on Wednesday will publicly receive the first doses of AstraZeneca bottled in the country.

New coronavirus cases grew 10% globally last week, driven by surges in Europe and the Americas, the WHO reported Wednesday, urging continued vaccinations.

Even before Thursday’s EMA announcement, the president of the European Commission made it clear that the AstraZeneca vaccine will remain a pillar of the EU’s vaccine strategy.

“I trust AstraZeneca, I trust the vaccines,” Ursula von der Leyen said.

But the suspensions of AstraZeneca shots in a cascading number of countries have served another setback to the EU’s vaccination drive, which has been plagued by shortages and other hurdles and is lagging well behind the campaigns in Britain and the U.S. More than half of the EU’s 15 million AstraZeneca doses so far are still in storage because of prior problems.

Almost as soon as France’s president froze the vaccinations Monday, top French officials started worrying about the impact on public opinion in a country where many already viewed the AstraZeneca vaccine as second-class and where vaccine skepticism is broad -– at a time when surging infections have again pushed intensive care units beyond capacity.

In Germany, where eight cases of blood clots are under investigation, officials defended the decision to suspend vaccinations for further investigation but appeared ready to resume them soon. Health Ministry spokesman Hanno Kautz said Wednesday: “It’s clear that the EMA decision is binding, and of course we will follow the EMA decision too.”

Lithuania’s president criticized its health minister’s decision to suspend the shots, saying it causes “enormous damage to entire vaccination process.”

The impact has reached beyond Europe, with people snubbing the AstraZeneca vaccine as subpar even when it is the only one available.

“The number of countries that have suspended the AstraZeneca vaccine has the potential to adversely impact vaccination rates,” said Ivo Vlaev of Warwick Business School, member of a group in the U.K.’s National Health Service aiming at combating vaccine hesitancy. “The currently unspecified nature of the vaccine’s side effects prompts people to imagine the worst case scenario. This is a powerful, emotional response.”

The EMA says thousands of people across the EU develop blood clots every year for a variety of reasons and that there were no reports of increased clotting incidents in the clinical studies of the AstraZeneca vaccine.

The company says there have been 37 reports of blood clots among the more than 17 million people who have received the vaccine across the EU and Britain.